Biote slightly beats Q3 revenue expectations, reaffirms 2025 revenue forecast

biote

05/11/2025 21:38

Overview

Biote Q3 2025 revenue slightly beats analyst expectations at $48 mln

Net income for Q3 2025 decreased to $9.2 mln from $12.7 mln last year

Company repurchased approximately one mln shares of Class A common stock

Outlook

Biote reiterates 2025 revenue guidance above $190 mln

Company expects 2025 Adjusted EBITDA above $50 mln

2025 procedure revenue expected to decrease at high single-digit rate

Result Drivers

PROCEDURE REVENUE DECLINE - Procedure revenue fell 10.4%, offset by 8.4% growth in dietary supplements revenue

GROSS MARGIN IMPROVEMENT - Gross profit margin improved to 71.8% due to efficiencies from vertical integration and cost management

INCREASED EXPENSES - Operating income decreased due to higher expenses, including the shift of the annual provider conference

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Slight Beat*
$48 mln
$47.76 mln (5 Analysts)
Q3 Adjusted EBITDA
$12.90 mln
Q3 Gross Margin
71.80%
Q3 Adjusted EBITDA Margin
26.90%
Q3 Operating Income
$8.30 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the professional information services peer group is "buy"

Wall Street's median 12-month price target for Biote Corp is $5.46, about 47.6% above its November 4 closing price of $2.86

The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release: ID:nBw3xRW9Ma

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)